CEBP CTRC-AACR San Antonio Breast Cancer Symposium 2008 Conference on Cancer Prevention - Washington, D.C.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kotova, N.
Right arrow Articles by Segerbäck, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotova, N.
Right arrow Articles by Segerbäck, D.
Cancer Epidemiology Biomarkers & Prevention Vol. 14, 2868-2872, December 2005
© 2005 American Association for Cancer Research

Urinary Thymidine Dimer as a Marker of Total Body Burden of UV-Inflicted DNA Damage in Humans

Natalia Kotova1,2, Kari Hemminki3 and Dan Segerbäck1

1 Department of Biosciences, Karolinska Institute, Huddinge; 2 Department of Genetics, Microbiology, and Toxicology, Stockholm University, Stockholm, Sweden; and 3 German Cancer Research Center, Heidelberg, Germany

Requests for reprints: Dan Segerbäck, Department of Biosciences, Karolinska Institute, Novum, S-141 57 Huddinge, Sweden. Phone: 46-8-608-9245; Fax: 46-8-608-1501. E-mail: dan.segerback{at}biosci.ki.se

High levels of DNA damage are induced in human skin following exposure to UV radiation. Cyclobutane thymidine dimer (T = T) is the most common of these lesions, which are enzymatically removed as oligonucleotides from DNA and further degraded before excretion in urine. Analysis of such repair products in the urine could serve as a biomarker of total body burden of UV exposure. The aim of this study was to examine the kinetics of T = T excretion following a single tanning session in a commercial solarium and to validate the method by delivering different doses. Ten individuals used the solarium for a total of 35 sessions of body tanning. Urine was collected before UV exposure and daily thereafter (up to 5 or 11 days) and T = T was analyzed using a very sensitive and quantitative 32P-postlabeling technique combined with high-performance liquid chromatography. Following exposure, T = T levels increased dramatically and reached a peak 3 days later; afterwards, the T = T levels gradually decreased. The total amount of T = T excreted differed about 5-fold among subjects given an equal dose. A 50% excretion time was calculated using the excretion data for the first 5 days and it was found to be between 55 and 76 hours for different individuals. There was a good correlation between the amount of T = T excreted during days 1 to 5 and the delivered UV dose. Reducing exposure time to 50% lowered the amount of T = T to 47%; if half of the lamps were covered, T = T decreased to 44%. Our data show that urinary T = T could be a suitable noninvasive biomarker for UV exposure; a finding which could also be applicable to studies in children. (Cancer Epidemiol Biomarkers Prev 2005;14(12):2868–72)




This article has been cited by other articles:


Home page
MutagenesisHome page
V. M. Arlt, E. Frei, and H. H. Schmeiser
ECNIS-sponsored workshop on biomarkers of exposure and cancer risk: DNA damage and DNA adduct detection and 6th GUM-32P-postlabelling workshop, German Cancer Research Center, Heidelberg, Germany, 29-30 September 2006
Mutagenesis, January 1, 2007; 22(1): 83 - 88.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
R. Turrisi, J. Stapleton, K. Mallett, and J. Hillhouse
Methods in skin cancer prevention: using a question-driven approach to guide the choice of assessment approaches.
Arch Dermatol, October 1, 2006; 142(10): 1348 - 1350.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.